Biotech · Public company · San Diego, CA, US

ADARx Pharmaceuticals, Inc.

Ticker ADRX · SEC CIK 0001802369

Track this companyFree. Adds ADARx Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials44 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

ADX-324Phase 3 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
ADX-324 Dose Level 1Phase 3 · Hereditary Angioedema (HAE)ClinicalTrials.gov · fetched Nov 12, 2026
ADX-324 Dose Level 2Phase 3 · Hereditary Angioedema (HAE)ClinicalTrials.gov · fetched Nov 12, 2026
ADX-038Phase 2 · Geographic Atrophy Secondary to Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
ADX-038 Dose Level 1Phase 2 · IgANClinicalTrials.gov · fetched Nov 12, 2026
ADX-038 Dose Level 2Phase 2 · IgANClinicalTrials.gov · fetched Nov 12, 2026

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)PHASE3 · RECRUITING · started Apr 2, 2026ClinicalTrials.gov NCT07428499 · fetched Nov 12, 2026
Phase 2 Study of ADX-038 in Participants With Geographic AtrophyPHASE2 · RECRUITING · started Nov 10, 2025ClinicalTrials.gov NCT06990269 · fetched Nov 12, 2026
Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseasePHASE2 · RECRUITING · started Aug 28, 2025ClinicalTrials.gov NCT06989359 · fetched Nov 12, 2026
STOP-HAE: A Phase 3 Study of ADX-324 in HAEPHASE3 · RECRUITING · started Aug 28, 2025ClinicalTrials.gov NCT06960213 · fetched Nov 12, 2026